Are CAR T cells the answer to myasthenia gravis therapy?
- PMID: 37353270
- DOI: 10.1016/S1474-4422(23)00211-9
Are CAR T cells the answer to myasthenia gravis therapy?
Conflict of interest statement
AM has received speaker or consultancy honoraria or financial research support (paid to his institution) from Alexion Pharmaceuticals, argenx, Axunio, Destin, Grifols, Hormosan Pharma, Janssen, Merck, Octapharma, UCB, and Xcenda. He serves as medical advisory board chairman of the German Myasthenia Gravis Society.
Comment on
-
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.Lancet Neurol. 2023 Jul;22(7):578-590. doi: 10.1016/S1474-4422(23)00194-1. Lancet Neurol. 2023. PMID: 37353278 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
